Ixoreal Biomed, the manufacturer of the advanced ashwagandha extract KSM-66®, has signed an exclusive agreement with Australia’s largest contract manufacturer Lipa Pharmaceuticals for the territories of Australia and New Zealand. KSM-66 can be used in many applications including nutraceuticals, functional foods and beverages.
“Ixoreal is delighted to partner with the industry leader Lipa Pharmaceuticals in Australia and New Zealand as our companies share the strong belief and deep commitment to the philosophy of discovering and bringing to market the best science-based ingredients that nature has to offer,” said Kartikeya Baldwa director of Ixoreal Biomed.
KSM-66 has recently received recognition at two of the nutrition industry's largest trade shows—being awarded "Innovative Ingredient of the Year" at Panacea in South Asia and being a finalist for the "Best Botanical" award by Engredea at Expo West in Anaheim.
“Lipa Pharmaceuticals is committed to sourcing and developing close relationships with manufacturers like Ixoreal who are dedicated to providing our great industry with scientifically validated and premium quality ingredients. We have no doubt that KSM-66 will be a huge success in our region as the science and quality of KSM-66 is world class” says Mr. Pejnovic CEO of Lipa Pharmaceuticals.
The clinically proven KSM-66 extract has been evaluated in several scientific studies which utilize the ‘gold standard’ randomized double blinded placebo controlled design. The studies conducted in humans prove that KSM-66 is a safe and potent adaptogen as it exhibits an incredible normalizing effect against common physical, chemical and biological stressors.